We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

BAP:NYSECredicorp Ltd. Analysis

Data as of 2026-05-19 - not real-time

$303.86

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Credicorp Ltd. (BAP) is trading just above its technical support at $300, with the RSI at 38 indicating near‑oversold conditions and a bearish MACD histogram confirming short‑term pressure. Volume is increasing, suggesting buying interest may be building as the price hovers around the $303.86 level. The stock’s trailing PE of 12.2 is well below the industry average of 16.7, while the forward PE of 9.3 signals further undervaluation. Revenue growth of 21.8% and robust operating margins (≈50%) underpin a strong earnings outlook, reflected in a forward EPS of 32.54. The dividend yield of 4.69% with a 45% payout ratio is supported by a hefty cash pile of $56.9 bn against moderate debt, indicating sustainability.
Target prices from analysts average $360, implying an upside of roughly 18% from current levels, and the company’s strategic focus on digital banking and loan quality could accelerate growth. While 30‑day volatility is high at >50% and beta near 1, the overall risk profile remains moderate, making a buy stance attractive across short, medium, and long horizons.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Price near technical support with rising volume
  • Attractive dividend yield and sustainable payout
  • Undervalued PE relative to peers

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Revenue growth exceeding 20% and strong operating margins
  • Analyst target price implying ~18% upside
  • Low forward PE indicating value upside

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Strategic digital banking initiatives driving future earnings
  • Robust cash position and manageable debt
  • Sustainable high dividend supporting total return

Key Metrics & Analysis

Financial Health

Revenue Growth21.80%
Profit Margin33.68%
P/E Ratio12.2
ROE19.15%
ROA2.77%
P/B Ratio2.1
Industry P/E16.7

Technical Analysis

TrendNeutral
RSI38.2
Support$300.00
Resistance$345.73
MA 20$322.43
MA 50$330.26
MA 200$295.52
MACDBearish
VolumeIncreasing
Fear & Greed Index89.61

Valuation

Target Price$360.57
Upside/Downside18.66%
GradeUndervalued
TypeGrowth
Dividend Yield4.69%

Risk Assessment

Beta0.95
Volatility52.66%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.